Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension

International Journal of Obesity

Volumn 35, Issue 2, 2011, Pages 270-278

  Francque, S ^a   Verrijken, A ^a   Mertens, I ^a   Hubens, G ^a   Van Marck, E ^a   Pelckmans, P ^a   Michielsen, P ^a   Van Gaal, L ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

insulin resistance; metabolic syndrome; non alcoholic fatty liver; portal hypertension; visceral fat

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; LIVER ENZYME;

ABDOMINAL OBESITY; ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEMODYNAMIC MONITORING; HEPATIC VEIN; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STEATOSIS; VEIN CATHETERIZATION; VENOUS PRESSURE;

BIOLOGICAL MARKERS; BIOPSY; BLOOD FLOW VELOCITY; FATTY LIVER; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; LIVER CIRCULATION; MALE; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS;

ANIMALIA;

EID: 79951676665     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2010.134     Document Type: Article

References (52)

1. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of non-alcoholic steato-hepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-143.
3. Selzner M, Clavien P. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-113. (Pubitemid 32240490)
4. Behrns K, Tsiotos G, DeSouza N, Krishna M, Ludwig J, Nagorney D. Hepatic steatosis as a potential risk factor for major hepatic resections. J Gastrointest Surg 1998; 2: 292-298. (Pubitemid 128409616)
5. Rao M, Papreddy K, Abecassis M, Hashimoto T. Regeneration of liver with marked fatty change following partial hepatectomy in rats. Dig Dis Sci 2001; 46: 1821-1826. (Pubitemid 32844146)
6. Selzner M, Rüdiger H, Sindram D, Madden J, Clavien. Mecha-nisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000; 32: 1281-1288.
7. Choi S, Diehl AM. Role of inflammation in non-alcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21: 702-707.
8. Seifalian A, Chidambaram V, Rolles K, Davidson B. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 1998; 4: 71-77. (Pubitemid 28053314)
9. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-393. (Pubitemid 39062856)
10. Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A et al. Non-alcoholic steatohepatitis induces non-fibrosis related portal hypertension associated with splanchnic vaso-dilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int 2010; 30: 365-375.
11. Lebrec D, Moreau R. Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol 2001; 13: 309-311. (Pubitemid 32319892)
12. Laleman W, Van Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005; 25: 1070-1090.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß-cell functioning from fasting glucose and insulin concen-trations in men. Diabetology 1985; 28: 412-419. (Pubitemid 15018832)
14. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17: 187-196. (Pubitemid 23133348)
15. Bucombe JR, Hilson AJW. Radionuclide investigations of the liver. Oxford Textbook of Clinical Hepatology, 2nd edn. Oxford University Press: Oxford, UK, 1999. pp 579-588.
16. Merkel C, Bolognesi M, Bellon S, Bianca S, Honisch B, Lampe H et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33: 836-842.
17. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923. (Pubitemid 36397405)
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
19. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome\a new worldwide definition. Lancet 2005; 366: 1059-1062. (Pubitemid 41338752)
20. Farrell G, George J, de la M Hall P, McCullough AJ. An introduction to NASH and related fatty liver disorders. Fatty Liver Disease; NASH and related disorders. Blackwell Publishing: USA, 2005; 1-12.
21. Cosgrove DO. Liver Anatomy In: Cosgrove D, Meire H, Dewbury K (eds). Abdominal and General Ultrasound vol. 1, 3rd edn. Churchill Livingstone: New York, 1994. pp 227-242.
22. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000; 132: 112-117. (Pubitemid 30044177)
23. Dardenne AN. The spleen. In: Cosgrove D, Meire H, Dewbury K (eds). Abdominal and General Ultrasound vol. 1, 3rd edn. Churchill Livingstone: New York, 1994. pp 351-366.
24. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-1271. (Pubitemid 30235957)
25. Prati D, Taioli E, Zanella A, Della Torre E, Buttelli S, Del Vecchio E et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
26. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-543. (Pubitemid 36571048)
27. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol 2003; 17: 38-42. (Pubitemid 36322210)
28. Tawalkar JA. Motion\all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol 2002; 16: 718-721.
29. Campbell MS, Reddy KR. The evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20: 249-259.
30. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M et al. Transjugular liver biopsy\indications, adequacy quality of specimens, and complications\A systematic review. JHepatology 2007; 47: 284-294. (Pubitemid 47021258)
31. Lebrec D, Godfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83: 338-340. (Pubitemid 12078215)
32. Groszmann R, Vorobioff JD, Gao H. Measurement of portal pressure: when, how and why to do it. Clin Liver Dis 2006; 10: 499-512. (Pubitemid 44879979)
33. Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liv Dis 2006; 26: 348-362. (Pubitemid 44632926)
34. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. for the nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321. (Pubitemid 40770284)
35. World Health Organisation (WHO). Obesity: preventing and mana-ging the global epidemic report of a WHO consultation. WHO Technical Report Series 894. World Health Organisation: Geneva, 2000.
36. Alberti KG, Zimmer P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553. (Pubitemid 28319935)
37. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210. (Pubitemid 10003180)
38. Puoti C, Bellis L. Steatosis and portal hypertension. Eur Rev Med Pharmacol Sci 2005; 9: 285-290. (Pubitemid 41387393)
39. DesprésJP, Lemieux I, Prud'homme D. Treatment ofobesity: need to focus on high risk abdominally obese patients. Br Med J 2001; 322: 716-720.
40. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657. (Pubitemid 34533559)
41. Rinella M, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplant 2001; 7: 409-413.
42. Egushi Y, Egushi T, Mizuka T, Ide Y, Yasutake T, Iwakini R et al. Visceral fat accumulation and insulin resistance are important factors in non-alcoholic liver disease. J Gastroenterol 2006; 41: 462-469. (Pubitemid 43941913)
43. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-763. (Pubitemid 38337655)
44. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
45. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421.
46. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007; 23: 193-198. (Pubitemid 46192974)
47. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000. (Pubitemid 43112663)
48. Verrijken A, Francque S, Mertens I, Talloen M, Peiffer F, Van Gaal L. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes 2010; 34: 899-907.
49. Francque S. Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH). In: Van Damme P, van Herck K, Michielsen P, Francque S, Shouval D (eds). Chronic Hepatitis & Other Liver Disease. Oxford Textbook of Public Health 5th edn. Oxford University Press: Oxford, UK, 2009. (Chapter 9) 16, pp 1249-1263.
50. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-761. (Pubitemid 29220775)
51. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of non-alcoholic fatty liver disease. Hepatology 2004; 40: 475-483. (Pubitemid 39062866)
52. Reaven GM. Role of insulin resistance in human diabetes. Diabetes 1988; 37: 1595-1607. (Pubitemid 19004941)